Endocrine tumors of the pancreas (EPTs) in multiple endocrine neoplasia (MEN1): up-date on prognostic factors, diagnostic procedures and treatment;Les tumeurs endocrines du pancréas lors de la néoplasie endocrinienne multiple type 1 (NEM1): actualités sur les facteurs pronostiques, l'imagerie et le traitement

Annales d'Endocrinologie

Volumn 68, Issue SUPPL. 1, 2007, Pages 1-8

  Libe R ^a,b,c,d,e   Chanson, P ^a,f  

^a INSERM   (France)

^b INSTITUT COCHIN   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Institut Cochin   (France)

^f BICÊTRE HOSPITAL   (France)

Author keywords

Chromogranin A; Endocrine pancreatic tumors; Multiple endocrine neoplasia type 1 (MEN1); Somatostatin analogues

Indexed keywords

ALPHA INTERFERON; CHROMOGRANIN A; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; KI 67 ANTIGEN; METHIONINE; PENTETREOTIDE; PENTETREOTIDE IN 111; PROTEIN INHIBITOR; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TUMOR MARKER;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BIOCHEMISTRY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER SURGERY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ENDOSCOPIC ECHOGRAPHY; GASTRINOMA; GENE MUTATION; GLUCAGONOMA; HORMONE INHIBITION; HUMAN; IMMUNOSTIMULATION; INCIDENCE; INSULINOMA; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; PREVALENCE; PROGNOSIS; RECOMMENDED DRUG DOSE; SCINTIGRAPHY; TREATMENT RESPONSE; VIPOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ISLET CELL; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PROGNOSIS;

EID: 35348936062     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2007.01.003     Document Type: Editorial

References (62)

1. Angeletti S., Corleto V., Schillaci O., et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 42 (1998) 792-794
2. Anthony L., Johnson D., Hande K., et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32 (1993) 217-223
3. Arnold R., Simon B., and Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 62 Suppl 1 (2000) 84-91
4. Bajetta E., Ferrari L., Martinetti A., et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86 (1999) 858-865
5. Bajetta E., Zilembo N., Di Bartolomeo M., et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 72 (1993) 3099-3105
6. Barakat M., Meeran K., and Bloom S. Neuroendocrine tumours. Endocr Relat Cancer 11 (2004) 1-18
7. Bartsch D., Langer P., Wild A., et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?. Surgery 128 (2000) 958-966
8. Benya R., Metz D., Venzon D., et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med 97 (1994) 436-444
9. Brandi M., Gagel R., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
10. Cadiot G., Vuagnat A., Doukhan I., et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'lÉtude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Étude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 116 (1999) 286-293
11. Carty S., Helm A., Amico J., et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 124 (1998) 1106-1113 discussion 1113-1104
12. Debray M., Geoffroy O., Laissy J., et al. Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 74 (2001) 1065-1070
13. Eriksson B., Renstrup J., Imam H., and Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 8 (1997) 1041-1044
14. Eriksson B., Skogseid B., Lundqvist G., Wide L., Wilander E., and Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65 (1990) 1883-1890
15. Evers B., Rady P., Sandoval K., et al. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Ann Surg 219 (1994) 596-601 discussion 602-594
16. Faiss S., Rath U., Mansmann U., et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60 (1999) 469-476
17. Fjallskog M., Sundin A., Westlin J., Oberg K., Janson E., and Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 19 (2002) 35-42
18. Fjallskog M., Granberg D., Welin S., et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 (2001) 1101-1107
19. Grant C. Gastrointestinal endocrine tumours. Insulinoma. Baillieres Clin Gastroenterol 10 (1996) 645-671
20. Hessman O., Lindberg D., Skogseid B., et al. Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas. Cancer Res 58 (1998) 377-379
21. Jensen R. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 243 (1998) 477-488
22. Kaltsas G., Besser G., and Grossman A. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25 (2004) 458-511
23. King C., Reznek R., Dacie J., and Wass J. Imaging islet cell tumours. Clin Radiol 49 (1994) 295-303
24. Kouvaraki M., Ajani J., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (2004) 4762-4771
25. Kouvaraki M., Shapiro S., Cote G., et al. Management of Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1. World J Surg 30 (2006) 643-653
26. Lamberts S., Krenning E., and Reubi J. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12 (1991) 450-482
27. Lo C., van Heerden J., Thompson G., Grant C., Soreide J., and Harmsen W. Islet cell carcinoma of the pancreas. World J Surg 20 (1996) 878-883 discussion 884
28. Lowney J., Frisella M., Lairmore T., and Doherty G. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 124 (1998) 1043-1048 discussion 1048-1049
29. Marini F., Falchetti A., Del Monte F., et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis (2006) 1-45
30. Maton P. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Gastroenterol Clin North Am 18 (1989) 897-922
31. Moertel C., Hanley J., and Johnson L. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced isletcell carcinoma. N Engl J Med 303 (1980) 1189-1194
32. Moertel C., Lefkopoulo M., Lipsitz S., Hahn R., and Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519-523
33. Nobels F., Kwekkeboom D., Coopmans W., et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82 (1997) 2622-2628
34. Norton J., Cromack D., Shawker T., et al. Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation. Ann Surg 207 (1988) 160-168
35. Norton J., Fraker D., Alexander H., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 (1999) 635-644
36. O'Connor D., and Deftos L. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 314 (1986) 1145-1151
37. Oberg K. Therapeutic alternative in metastasizing neuroendocrine tumors. In carefully selected cases liver transplantation is possible. Lakartidningen 96 (1999) 3745-3747
38. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12 Suppl 2 (2001) S111-S114
39. Oberg K., and Eriksson B. The role of interferons in the management of carcinoid tumours. Br J Haematol 79 Suppl 1 (1991) 74-77
40. Oberg K., and Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19 (2005) 753-781
41. Orlefors H., Sundin A., Garske U., et al. Whole-body (11) C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90 (2005) 3392-3400
42. Panzuto F., Severi C., Cannizzaro R., et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 27 (2004) 6-11
43. Peghini P., Iwamoto M., Raffeld M., et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 8 (2002) 2273-2285
44. Pellegata N., Quintanilla-Martinez L., Siggelkow H., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 103 (2006) 15558-15563
45. Ramage J., Davies A., Ardill J., et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54 Suppl 4 (2005) iv1-iv16
46. Rigaud G., Missiaglia E., Moore P., et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 61 (2001) 285-292
47. Rosch T., Lightdale C., Botet J., et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 326 (1992) 1721-1726
48. Rubin J., Ajani J., Schirmer W., et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17 (1999) 600-606
49. Schindl M., Kaczirek K., Kaserer K., and Niederle B. Is the new classification of neuroendocrine pancreatic tumors of clinical help?. World J Surg 24 (2000) 1312-1318
50. Soga J., and Yakuwa Y. Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg 5 (1998) 312-319
51. Soga J., and Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 17 (1998) 389-400
52. Soga J., and Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 18 (1999) 13-22
53. Soga J., Yakuwa Y., and Osaka M. Insulinoma/hypoglycemic syndrome: a statistical evaluation of 1085 reported cases of a Japanese series. J Exp Clin Cancer Res 17 (1998) 379-388
54. Termanini B., Gibril F., Reynolds J., et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112 (1997) 335-347
55. Thompson N. Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Oncol Clin N Am 7 (1998) 881-891
56. Triponez F., Goudet P., Dosseh D., et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 30 (2006) 654-662 discussion 663-654
57. Vinik A., Strodel W., Eckhauser F., Moattari A., and Lloyd R. Somatostatinomas, PPomas, neurotensinomas. Semin Oncol 14 (1987) 263-281
58. Wang E., Ebrahimi S., Wu A., Kashefi C., Passaro Jr. E., and Sawicki M. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 58 (1998) 4417-4420
59. Wiedenmann B., Jensen R., Mignon M., et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 22 (1998) 309-318
60. Yu F., Venzon D., Serrano J., et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17 (1999) 615-630
61. Zhuang Z., Vortmeyer A., Pack S., et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 57 (1997) 4682-4686
62. Zimmer T., Stolzel U., Bader M., et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 39 (1996) 562-568